UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on Allscripts Healthcare Solutions Following Solid Bookings Performance

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions MDRX, but removed the $21.00 price target. In the report, Morgan Stanley noted, “1Q14 bookings of $223M were up 25.5% y/y, with -18.6% seq decline reflecting seasonality (CERN was down -17.8% seq). Growth y/y reflected strength in ambulatory, population health management (PHM), managed IT services and outsourcing. PHM accounted for 36% of bookings; ex-PHM we est. core bookings were up 4.3% y/y and down -10.2% seq. MDRX added 130 new clients in the qtr, with ambulatory and PHM (particularly Care Management) driving new wins. SaaS contracts were 42% of bookings, up from 25% in 1Q13 and inline with 44% in 4Q13. SaaS revenues were 15% of total revenues up from 13% in 1Q13 and 14% in 4Q13. Driven by increasing SaaS mix, recurring revenues were 78% in the qtr, up from 74% in both 1Q13 and 4Q13.” Allscripts Healthcare Solutions closed on Thursday at $14.99.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMorgan StanleyRicky R. Goldwasser
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!